It is unknown whether the glycosaminoglycan drug sulodexide interferes with transforming growth factorβ1—a member of heparin-binding family and a potent regulator of human biology and diseases. Hence, a 2-week pilot study was performed in 11 healthy men. Sulodexide was initially administered intravenously in a single dose, then—orally for 12 days and—again intravenously on study completion. Initial injection had no effect on activated form of the growth factor measured in plasma after 10 and 120 min; no change was also observed after 120 min from drug ingestion on day 7. On final intravenous administration, the growth factor levels increased by almost 60% after 10 min and remained elevated; the 120-min levels directly correlated with sulodexide dosage. Baseline cytokine levels decreased during the 2-week trial by more than 50%. In conclusion, transforming growth factor-β1 release and likely downregulation of its expression may constitute novel pharmacological effects of sulodexide.
Harenberg J.Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998;18:1-20.
2.
Ofosu FAPharmacological actions of sulodexide. Semin Thromb Hemost . 1998;24:127-138.
3.
Abaterusso C. , Gambaro G.The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol . 2006;5:211-222.
4.
Wijnhoven TJ , Lensen JF, Rops AL, et al. Anti-proteinuric effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther. 2007;9:364-377.
5.
Lauver DA, Lucchesi BRSulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. 2006;24: 214-226.
6.
Gozdzikiewicz J., Borawski J., Mysliwiec M.Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost. 2007. doi. 10.1177/ 1076029607304722..
7.
Borawski J., Zbroch E., Rydzewska-Rosolowska A., Pawlak K., Mysliwiec M.Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II. J Nephrol. 2007;20:370-372.
8.
Elsayed E., Becker RCThe impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis. 2003;15:11-18.
Taipale J., Keski-Oja J.Growth factors in the extracellular matrix. FASEB J. 1997;11:51-59.
17.
Taylor KR, Gallo RLGlycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006;20:9-22.
18.
Rider CCHeparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans. 2006;34:458-460.
19.
Chen Q., Sivakumar P., Barley C., et al. Potential role for heparan sulfate proteoglycans in regulation of TGF-beta by modulating assembly of latent TGF-beta binding protein-1 (LTBP-1) . J Biol Chem. 2007;282:26418-26430.
20.
Grainger DJ , Mosedale DE, Metcalfe JC (2000) TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev. 2000;11:133-145.
21.
Annes JP, Munger JS, Rifkin DBMaking sense of latent TGF-beta activation. J Cell Sci. 2003;116:217-224.
22.
Ceol M., Gambaro G., Sauer U., et al. Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol. 2000;11:2324-2336.
23.
Weigert C., Brodbeck K., Haring HU, Gambaro G., Schleicher EDLow-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int. 2001 ;60:935-943.
24.
Ceol M., Vianello D., Schleicher E., et al. Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis. J Nephrol. 2003;16:210-218.
25.
Pecly IM, Goncalves RG, Rangel EP, et al. Effects of low molecular weight heparin in obstructed kidneys: decrease of collagen, fibronectin and TGF-beta, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration. Nephrol Dial Transplant. 2006;21:1212-1222.
26.
Naumnik B., Borawski J., Pawlak K., Mysliwiec M.Enoxaparin but not unfractionated heparin causes a dose-dependent increase in circulating TGF-beta1 during haemodialysis: a cross-over study. Nephrol Dial Transplant. 2007;22:1690-1696.
27.
McCaffrey TA , Falcone DJ, Brayton CF, Agarwal LA, Welt FG, Weksler BBTransforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol. 1989;109:441-448.
28.
Tardieu M., Bourin MC, Desgranges P., Barbier P., Barritault D., Caruelle JPMesoglycan and sulodexide act as stabilizers and protectors of fibroblast growth factors (FGFs). Growth Factors. 1994 ;11: 291-300.
29.
Borawski J. , Dubowski M., Pawlak K., Mysliwiec M.Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007;558:167-171.
